[1] 潘锋. 铂类药物是妇科恶性肿瘤化疗的基本药物[J]. 中国当代医药, 2021, 28(30): 1-3.
[2] YANG L, XIE H J, LI Y Y, et al. Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer (review)[J]. Oncol Rep, 2022, 47(4): 82.
[3] ROSE P G. Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments: a clinical perspective[J]. Cancer Drug Resist, 2022, 5(2): 415-423.
[4] BINJU M, PADILLA M A, SINGOMAT T, et al. Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer-a mini review[J]. Biochim Biophys Acta Gen Subj, 2019, 1863(2): 371-378.
[5] ICARD P, SHULMAN S, FARHAT D, et al. How the Warburg effect supports aggressiveness and drug resistance of cancer cells-[J]. Drug Resist Updat, 2018, 38: 1-11.
[6] BHATTACHARYA B, MOHD OMAR M F, SOONG R. The Warburg effect and drug resistance[J]. Br J Pharmacol, 2016, 173(6): 970-979.
[7] HUDSON C D, SAVADELIS A, NAGARAJ A B, et al. Altered glutamine metabolism in platinum resistant ovarian cancer[J]. Oncotarget, 2016, 7(27): 41637-41649.
[8] VIALE A, CORTI D, DRAETTA G F. Tumors and mitochondrial respiration: a neglected connection[J]. Cancer Res, 2015, 75(18): 3685-3686.
[9] GHONEUM A, ALMOUSA S, WARREN B, et al. Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer[J]. Semin Cancer Biol, 2021, 77: 83-98.
[10] CHENG C M, GENG F, CHENG X, et al. Lipid metabolism reprogramming and its potential targets in cancer[J]. Cancer Commun, 2018, 38(1): 1-14.
[11] YANG J, ZAMAN M M, VLASAKOV I, et al. Adipocytes promote ovarian cancer chemoresistance[J]. Sci Rep, 2019, 9: 13316.
[12] LEMBERGER L, WAGNER R, HELLER G, et al. Pharmacological inhibition of lipid import and transport proteins in ovarian cancer[J]. Cancers, 2022, 14(23): 6004.
[13] Criscuolo D, Avolio R, Calice G, et al. Cholesterol Homeostasis Modulates Platinum Sensitivity in Human Ovarian Cancer[J]. Cells, 2020, 9(4): 828.
[14] ZHENG L, LI L, LU Y, et al. SREBP2 contributes to cisplatin resistance in ovarian cancer cells[J]. Exp Biol Med Maywood N J, 2018, 243(7): 655-662.
[15] CHANG W C, WANG H C, CHENG W C, et al. LDLR-mediated lipidome-transcriptome reprogramming in cisplatin insensitivity[J]. Endocr Relat Cancer, 2020, 27(2): 81-95.
[16] HUANG X Y, WEI X, QIAO S J, et al. Low density lipoprotein receptor (LDLR) and 3-hydroxy-3-methylglutaryl coenzyme a reductase (HMGCR) expression are associated with platinum-resistance and prognosis in ovarian carcinoma patients[J]. Cancer Manag Res, 2021, 13: 9015-9024.
[17] WU Y F, SI R R, TANG H, et al. Cholesterol reduces the sensitivity to platinum-based chemotherapy via upregulating ABCG2 in lung adenocarcinoma[J]. Biochem Biophys Res Commun, 2015, 457(4): 614-620.
[18] AMOROSO M R, MATASSA D S, AGLIARULO I, et al. TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial-mesenchymal transition[J]. Cell Death Dis, 2016, 7(12): e2522.
[19] DAR S, CHHINA J, MERT I, et al. Bioenergetic adaptations in chemoresistant ovarian cancer cells[J]. Sci Rep, 2017, 7(1): 8760.
[20] TAN Y Y, LI J J, ZHAO G Y, et al. Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells[J]. Nat Commun, 2022, 13(1): 4554.
[21] NIEMAN K M, KENNY H A, PENICKA C V, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth[J]. Nat Med, 2011, 17(11): 1498-1503.
[22] MUKHERJEE A, CHIANG C Y, DAIFOTIS H A, et al. Adipocyte-induced FABP4 expression in ovarian cancer cells promotes metastasis and mediates carboplatin resistance[J]. Cancer Res, 2020, 80(8): 1748-1761.
[23] LADANYI A, MUKHERJEE A, KENNY H A, et al. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis[J]. Oncogene, 2018, 37(17): 2285-2301.
[24] JAYAWARDHANA A M D S, STILGENBAUER M, DATTA P, et al. Fatty acid-like Pt(IV) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36[J]. Chem Commun Camb Engl, 2020, 56(73): 10706-10709.
[25] WEI X, SHI J J, LIN Q H, et al. Targeting ACLY attenuates tumor growth and acquired cisplatin resistance in ovarian cancer by inhibiting the PI3K-AKT pathway and activating the AMPK-ROS pathway[J]. Front Oncol, 2021, 11: 642229.
[26] JHA V, GALATI S, VOLPI V, et al. Discovery of a new ATP-citrate lyase (ACLY) inhibitor identified by a pharmacophore-based virtual screening study[J]. J Biomol Struct Dyn, 2021, 39(11): 3996-4004.
[27] UEDA S M, YAP K L, DAVIDSON B, et al. Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas[J]. J Oncol, 2010, 2010: 285191.
[28] BAUERSCHLAG D O, MAASS N, LEONHARDT P, et al. Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer[J]. J Transl Med, 2015, 13: 146.
[29] UDDIN S, JEHAN Z, AHMED M, et al. Overexpression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and Its inhibition potentiates cisplatin-induced apoptosis[J]. Mol Med, 2011, 17(7/8): 635-645.
[30] PAPAEVANGELOU E, ALMEIDA G S, BOX C, et al. The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model[J]. Int J Cancer, 2018, 143(4): 992-1002.
[31] HUANG D Q, CHOWDHURY S, WANG H, et al. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer[J]. Cell Rep Med, 2021, 2(12): 100471.
[32] ZHU J R, WU G Y, SONG L B, et al. NKX2-8 deletion-induced reprogramming of fatty acid metabolism confers chemoresistance in epithelial ovarian cancer[J]. EBioMedicine, 2019, 43: 238-252. |
